<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02600052</url>
  </required_header>
  <id_info>
    <org_study_id>06704028420</org_study_id>
    <nct_id>NCT02600052</nct_id>
  </id_info>
  <brief_title>Efficacy of Pattern Respiratory PNF Associated Aerobic Training on Lung Volumes and 6MWT Test in Parkinson Individuals</brief_title>
  <official_title>Efficacy of Pattern Respiratory Proprioceptive Neuromuscular Facilitation Associated With Aerobic Training on the Volumes, Lung Capacity and Six-minute Walking Test in Individuals With Parkinson: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal de Pernambuco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal de Pernambuco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      INTRODUCTION:

      Parkinson's disease (PD) is a neurodegenerative disorder that causes motor disorders such as
      bradykinesia, rigidity and tremor. In addition to the motor symptoms occurring in the overall
      PD patients, mostly there is associated respiratory disorders. The respiratory impairment may
      be due by postural changes, limiting the flexibility and expandability of the chest wall
      causing decreased lung volumes and flows. So the exercise Proprioceptive Neuromuscular
      Facilitation (PNF) is a tool designed to reduce the changes in respiratory function, the
      commitment of the respiratory muscles, and allows greater flexibility of the chest wall,
      reducing the rigidity of the rib cage. To evaluate the effects of respiratory pattern of
      Proprioceptive Neuromuscular Facilitation on the distribution of pulmonary ventilation,
      compartmental volumes of diaphragmatic mobility and functional capacity in patients with
      Parkinson's disease.

      METHODS:

      The study is a clinical trial randomized, in which participants to be elected for the study
      should present diagnosis of PD, staging of disease between II and III according to Hoehn and
      Yahr. Initially, the participants will undergo the collection of data on medical history,
      assessment of pulmonary function by spirometry and respiratory muscle strength measured by
      the manometer. Then will undergo evaluation of the breathing pattern and tricompartmental
      distribution of the volume of the chest wall by hemithorax by Plethysmography Optoelectronic;
      Quantify the mobility of the right diaphragm in total lung capacity for maneuver and during
      the current volume by ultrasonography. After the evaluation, participants will undergo
      intervention which will consist of three stages: first occur first session of the PNF later
      aerobic training for 30 minutes, ending with one PNF session.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LUNG VOLUME</measure>
    <time_frame>1 MONTH</time_frame>
    <description>BY OPTOELECTRONIC PLETHYSMOGRAPHY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WALKING DISTANCE, VO2, VCO2</measure>
    <time_frame>1 MONTH</time_frame>
    <description>SIX-MINUTE WALK TEST PLUS CÃ“RTEX</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DIAPHRAGM MOBILITY</measure>
    <time_frame>1 MONTH</time_frame>
    <description>ULTRASOUND</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DIAPHRAGM THICKNESS</measure>
    <time_frame>1 MONTH</time_frame>
    <description>ULTRASOUND</description>
  </secondary_outcome>
  <other_outcome>
    <measure>PRESSURE RESPIRATORY MAXIMAL</measure>
    <time_frame>1 MONTH</time_frame>
    <description>BY MANOVACUOMETER</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>GPNF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be submitted to aerobic training, with prior application of PNF technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GCONTROL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be submitted to aerobic training, with prior application of relax technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PNF</intervention_name>
    <description>RESPIRATORY PATTERN PROPRIOCEPTIVE NEUROMUSCULAR FACILITATION</description>
    <arm_group_label>GPNF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>treadmill</intervention_name>
    <description>AEROBIC TRAINING</description>
    <arm_group_label>GPNF</arm_group_label>
    <arm_group_label>GCONTROL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with stage II and III between the Hoehn and Yahr classification;

          -  minimum score of 28 on the Mini Mental Examination for Parkinson.

        Exclusion Criteria:

          -  individuals with rheumatologic or orthopedic diseases or deformities / abnormalities
             in the spine that compromise the respiratory mechanics;

          -  respiratory comorbidities;

          -  history of smoking;

          -  history of thoracic or abdominal surgery;

          -  clinical instability characterized by infections and / or hemodynamic defined as
             greater than 150 bpm heart rate or systolic blood pressure less than 90 mmHg;

          -  Not present exchange of the drug in the last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlos Rego Barros</last_name>
    <phone>+55 81 21268496</phone>
    <email>carlosregobarros@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Armele Dornelas</last_name>
    <phone>+55 81 21268496</phone>
    <email>armeledornelas@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidade Federal de Pernambuco</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50740560</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Rego Barros</last_name>
      <phone>+55 81 21268496</phone>
      <email>carlosregobarros@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Armele Dornelas</last_name>
      <phone>+55 81 21268496</phone>
      <email>armeledornelas@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Costa A, Bagoj E, Monaco M, Zabberoni S, De Rosa S, Mundi C, Caltagirone C, Carlesimo GA. Mini mental Parkinson test: standardization and normative data on an Italian sample. Neurol Sci. 2013 Oct;34(10):1797-803. doi: 10.1007/s10072-013-1342-8. Epub 2013 Mar 12.</citation>
    <PMID>23479031</PMID>
  </reference>
  <reference>
    <citation>Isella V, Mapelli C, Morielli N, De Gaspari D, Siri C, Pezzoli G, Antonini A, Poletti M, Bonuccelli U, Picchi L, Napolitano A, Vista M, Greco A, Appollonio IM. Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson's disease. Neurol Sci. 2013 Oct;34(10):1751-8. doi: 10.1007/s10072-013-1328-6. Epub 2013 Feb 20.</citation>
    <PMID>23423464</PMID>
  </reference>
  <reference>
    <citation>Carvalho A, Barbirato D, Araujo N, Martins JV, Cavalcanti JL, Santos TM, Coutinho ES, Laks J, Deslandes AC. Comparison of strength training, aerobic training, and additional physical therapy as supplementary treatments for Parkinson's disease: pilot study. Clin Interv Aging. 2015 Jan 7;10:183-91. doi: 10.2147/CIA.S68779. eCollection 2015.</citation>
    <PMID>25609935</PMID>
  </reference>
  <reference>
    <citation>Pereira CA, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol. 2007 Jul-Aug;33(4):397-406. English, Portuguese.</citation>
    <PMID>17982531</PMID>
  </reference>
  <reference>
    <citation>ALIVERTI A, PEDOTTI A. Opto-electronic Plethysmography. v. c, 2002.</citation>
  </reference>
  <reference>
    <citation>Testa A, Soldati G, Giannuzzi R, Berardi S, Portale G, Gentiloni Silveri N. Ultrasound M-mode assessment of diaphragmatic kinetics by anterior transverse scanning in healthy subjects. Ultrasound Med Biol. 2011 Jan;37(1):44-52. doi: 10.1016/j.ultrasmedbio.2010.10.004.</citation>
    <PMID>21144957</PMID>
  </reference>
  <reference>
    <citation>Neder JA, Andreoni S, Lerario MC, Nery LE. Reference values for lung function tests. II. Maximal respiratory pressures and voluntary ventilation. Braz J Med Biol Res. 1999 Jun;32(6):719-27.</citation>
    <PMID>10412550</PMID>
  </reference>
  <reference>
    <citation>MOORE, V. C. Spirometry: Step by step. Breathe, v. 8, n. 3, p. 233-240, 2012</citation>
  </reference>
  <reference>
    <citation>Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J. 2005 Jul;26(1):153-61. Review.</citation>
    <PMID>15994402</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2015</study_first_posted>
  <last_update_submitted>June 22, 2016</last_update_submitted>
  <last_update_submitted_qc>June 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal de Pernambuco</investigator_affiliation>
    <investigator_full_name>Carlos Rego Barros</investigator_full_name>
    <investigator_title>researcher master</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

